- Home
- SOPH vs MGTX Comparison
SOPH vs MGTX Comparison
Compare SOPH & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | MGTX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.4M | 665.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SOPH | MGTX |
|---|---|---|
| Price | $5.25 | $7.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $23.83 |
| AVG Volume (30 Days) | 83.2K | ★ 478.9K |
| Earning Date | 03-03-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $73,297,000.00 | $27,417,000.00 |
| Revenue This Year | $18.32 | N/A |
| Revenue Next Year | $15.61 | $619.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.66 | ★ 96.83 |
| 52 Week Low | $2.58 | $4.55 |
| 52 Week High | $5.55 | $9.73 |
Technical Indicators
Market Signals| Indicator | SOPH | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.30 | 40.70 |
| Support Level | $4.62 | $7.00 |
| Resistance Level | $5.55 | $8.08 |
| Average True Range (ATR) | 0.28 | 0.42 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 71.29 | 26.43 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.